Kewaunee Scientific Corporation (KEQU)

From the record

Kewaunee Scientific Corporation's filings since 2017 show 3 warning events of 2 kinds: an auditor change (8-K item 4.01, 2 times, the latest 2022-06-06); a late-report notice (Form NT 10-K or NT 10-Q, the latest 2021-12-15) (its current reports).

From the record

Kewaunee Scientific Corporation's 10 filed years say what it did: revenue went from $139 million in fiscal 2017 to $282 million in fiscal 2026, up 8.2% a year; it rose in 6 of 9 years; the deepest fall was 7% from fiscal 2018 to fiscal 2019; net income was positive in 7 of 10 of those years (its annual reports).

From the record

Over the 3 fiscal years to 2026-04-30, Kewaunee Scientific Corporation's diluted share count grew about 0.9% a year, and dividends and buybacks returned about 7% of its operating cash flow over 3 years (its filed statements). Its officers and directors filed 11 sales and 0 purchases of their own stock on the open market in the year to 2026-09-30 (their Form 4 filings).

From the record

Return on equity: in the fiscal year ended 2026-04-30, Kewaunee Scientific Corporation earned about 13 cents of profit for every dollar of shareholders' money, and gross profitability: its products earned about 45 cents per dollar of everything the company owns. Leverage: it owed about 58 cents per dollar of assets, and net share issuance: its share count grew 0.1% over the year (the filed statements).

From the record

Kewaunee Scientific Corporation's standing among 23 graded names in its industry family: revenue of $282 million in fiscal 2026 ranks in the bottom 30% by size; a net margin of 3.4% ranks in the bottom 46%; revenue growth of 8.7% a year over the last 3 filed years ranks in the top 46% (its annual reports).

From the record

Kewaunee Scientific Corporation's leadership, from its insiders' filings and its current reports: the chief executive on the record is Hull, Thomas David III (President & CEO, as filed), filing under that title since 2019-06-21, 7.4 years (top 32% of its family); the 9 officers and directors filing in the last fifteen months have been on the record a median of 8.3 years (top 9%); 2 officer or director changes were reported on Form 8-K since 2023-11-13, against the 9 people in charge now (top 13%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.

From the record

Kewaunee Scientific Corporation's room to grow, from the newest filed statements (fiscal 2026): cash of $10 million against debt of $20 million leaves -5.7% of its assets as net cash, bottom 40% of its family; cash from operations less capital spending is 5.2% of revenue (bottom 43%); a gross margin of 28.5% (bottom 18%); research spending of 0.3% of revenue (bottom 8%) (its annual report).

From the record

Kewaunee Scientific Corporation's growth drivers, from the filed years to fiscal 2026: revenue grew 8.7% a year over the last three filed years against 8.2% over all 10, speeding up (top 24% of its family); the newest year grew 17.3% (top 20%); research spending grew -3.9% a year (bottom 34%); capital spending grew -1.7% a year (bottom 37%) (its annual reports). Kewaunee Scientific Corporation reported 2 lines of business in fiscal 2025: Domestic Operations at $179 million, International Operations at $61 million. 1 of 2 grew in the latest filed year, and the largest line is 75% of revenue (its annual report).

From the record

Kewaunee Scientific Corporation's newest year against its own record: revenue of $282 million in fiscal 2026 came in 12% above the $252 million its prior three years' pace pointed to (top 16% of its family); net income of $10 million against a prior three-year average of $10 million (bottom 20%); a net margin of 3.4% against 4.8% before (bottom 20%) (its annual reports).